Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Sign Up to like & getrecommendations! Published in 2020 at "Gastric Cancer"
DOI: 10.1007/s10120-020-01094-0
Abstract: Background AT-rich interactive domain 1A ( ARID1A ) is a tumor suppressor gene that is frequently mutated in gastric cancer (GC). Although ARID1A mutations are not a druggable target for conventional treatments, novel therapeutic strategies… read more here.
Keywords: deficient; ezh2 inhibitors; arid1a deficient; cancer ... See more keywords
Targeting USP9X-AMPK axis in ARID1A-deficient hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Cellular and molecular gastroenterology and hepatology"
DOI: 10.1016/j.jcmgh.2022.03.009
Abstract: BACKGROUND & AIMS Hepatocellular carcinoma(HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-Rich Interaction Domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in… read more here.
Keywords: hepatocellular carcinoma; hcc; targeting usp9x; usp9x ampk ... See more keywords
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2019.10.002
Abstract: OBJECTIVE Ovarian clear cell carcinoma (OCCC) is often resistant to conventional, standard chemotherapy using cytotoxic drugs. OCCC harbors a unique genomic feature of frequent (approximately 50%) ARID1A deficiency. The present study was performed to investigate… read more here.
Keywords: gemcitabine; arid1a deficient; deficient occc;
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.999626
Abstract: ARID1A is frequently mutated in colorectal cancer (CRC) cells. Loss of ARID1A function compromises DNA damage repair and increases the reliance of tumor cells on ATR-dependent DNA repair pathways. Here, we investigated the effect of… read more here.
Keywords: arid1a deficient; vulnerability arid1a; atr inhibitor; deficient ... See more keywords
Morphological, clinical and molecular characteristics in ARID1a‑deficient microsatellite‑stable oesophageal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Oncology letters"
DOI: 10.3892/ol.2023.13840
Abstract: Publications describe the relevance of the AT-rich interactive domain-containing protein 1A (ARID1a) mutation in gastric adenocarcinoma, which occurs predominantly in the microsatellite instable (MSI)- and Epstein-Barr virus (EBV)-associated subtypes. It is unclear whether potential therapeutic,… read more here.
Keywords: arid1a deficient; microsatellite stable; oesophageal adenocarcinoma; loss ... See more keywords
Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "PeerJ"
DOI: 10.7717/peerj.12750
Abstract: Background Genetic alterations in ARID1A were detected at a high frequency in cholangiocarcinoma (CCA). Growing evidence indicates that the loss of ARID1A expression leads to activation of the PI3K/AKT pathway and increasing sensitivity of ARID1A-deficient… read more here.
Keywords: akt pathway; pi3k akt; arid1a deficient; cca ... See more keywords